TR399 for erectile dysfunction

Over 400 million males suffer from erectile dysfunction (ED) in the world. Currently, phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra) are used to treat ED orally and their annual sales are up to 4 billion USD.Although PDE5 inhibitors show a satisfied efficacy in treatment of ED syndrome, the undesired side effects somehow happen after consumption.Therefore, to find the useful methods or dosages for elimination of cardiovascular side effects and sudden death, especially in aged users over 40 years old, becomes a straightforward improvement of PDE5 inhibitors. Tritech focuses on the development of new dosage and transdermal delivery to increase the clinical values and lower the side effects of PDE5 inhibitors. Our product, TR399 a topical vardenafil gel, is designed to use once a day continueously. TR399 has completed the phase I/IIa trial with satisfied results such as side effect free, extremely low Cmax and long lasting efficacy.